

COMPANY OVERVIEW

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.

RECENT NEWS

[Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update](#)

Aug 9 2018, 8:00 AM EDT

[Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV](#)

Jun 28 2018, 7:35 AM EDT

[Cocrystal Pharma Announces Inclusion in Russell Microcap® Index](#)

Jun 25 2018, 8:00 AM EDT

STOCK OVERVIEW

Symbol	COCP
Exchange	Nasdaq
Market Cap	123.88m
Last Price	\$4.14
52-Week Range	\$1.61 - \$9.00

INVESTOR RELATIONS

Jenene Thomas Communications
Jenene Thomas
T: 833-475-8247
cocp@jtcir.com

MANAGEMENT TEAM

Gary Wilcox, Ph.D.

Vice Chairman and Interim Chief Executive Officer

Sam Lee, Ph.D.

President

James J. Martin

Chief Financial Officer

COCRYSTAL PHARMA, INC.

1860 Montreal Rd.
Tucker, GA 30084
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

